Roche Holding AG
1ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
stocks
Chart of the Week: AI market leader is now surprisingly cheap
This AI beneficiary may still be one of the market’s most compelling bargains.
stocks
Weekly earnings wrap: Rio Tinto leads the way
A closer look at the key earnings results from the first week of August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,454.10 | 44.20 | 0.47% |
| CAC 40 | 8,669.30 | 0.00 | 0.00% |
| DAX 40 | 26,126.30 | 76.05 | -0.29% |
| Dow JONES (US) | 54,349.12 | 263.24 | 0.49% |
| FTSE 100 | 10,888.30 | 8.92 | 0.08% |
| HKSE | 25,420.91 | 494.91 | -1.91% |
| NASDAQ | 26,363.44 | 221.55 | -0.83% |
| Nikkei 225 | 65,402.27 | 898.17 | -1.35% |
| NZX 50 Index | 13,961.69 | 35.49 | -0.25% |
| S&P 500 | 7,723.55 | 12.97 | -0.17% |
| S&P/ASX 200 | 9,272.10 | 42.30 | 0.46% |
| SSE Composite Index | 3,878.92 | 0.49 | 0.01% |